NBE Therapeutics AG, Basel, Switzerland, and SOTIO a.s., Prague, Czech Republic, have entered into a collaboration for the development of next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. Under the agreement, NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on NBE’s proprietary antibody discovery and conjugation platforms, including NBE’s Transpo-mAbTM antibody platform, its site-specific SMACTM conjugation technology and its novel ultra-potent toxin platform. SOTIO will have global responsibility for clinical development, registration and commercialization of the ADC products.
Upon exercise of the target options, NBE will be eligible for an option exercise fee, as well as milestone payments and royalties based on global net sales of the products. In addition, NBE will be reimbursed for its R&D expenses incurred in connection with the development of the product in collaboration with SOTIO.
As part of the deal, PPF Group, the owner of SOTIO, has committed to invest CHF10m in the next financing round of NBE.
Download full press release as PDF.